Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device.

Slides:

Advertisements

Similar presentations

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,

Advertisements

Soft robotic device applied to the RV in a pressure overload model of RHF. Soft robotic device applied to the RV in a pressure overload model of RHF. (A.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4. Local application of FR provides prolonged protection against Gq-dependent airway constriction in normal and OVA-sensitized mice in vivo. Local.

Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 5 Quantitative assessment of the efficacy of the tissue-engineered implant to heal the TMJ disc defect. Quantitative assessment of the efficacy of.

Fig. 1 ZIKV RNA in blood and tissues.

Consolidated Standards of Reporting Trials flow diagram of VRC trial

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Filipin staining of marginal gyrus of cerebral cortex in NPC cats

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 3. Comparison of prediction performance.

Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

In vivo release of doxycycline hyclate from the GRS in a swine model

Fig. 2 Fabrication and in vitro release of TB antibiotics from individual drug pills. Fabrication and in vitro release of TB antibiotics from individual.

Fig. 3 Glucose- and structure-dependent insulin release.

Soft robotic device applied to the RV in a pressure overload model of RHF. Soft robotic device applied to the RV in a pressure overload model of RHF. (A.

Fig. 2 LYM attractor metagene.

Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

Fig. 5. Col IV–Ac2-26 NPs decrease lesion area, necrotic area, and oxidative stress in brachiocephalic arterial plaques. Col IV–Ac2-26 NPs decrease lesion.

Colonization in tumor models and different modes of administration

Fig. 5. Vitamin B12 supplementation in the host altered the transcriptome of P. acnes in the skin microbiota. Vitamin B12 supplementation in the host altered.

Fig. 4 Device accuracy results (n = 32 users).

Fig. 7 BMS reduces the elevated expression of type I IFN–regulated genes both ex vivo in blood from patients with lupus and in a phase 1 study of.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

Fig. 4. Long-term persistence of CTL019 cells and polyfunctionality in patients achieving CR. Long-term persistence of CTL019 cells and polyfunctionality.

The microchip-based drug delivery device and overview of study design

Fig. 7. CIVO performance in canine lymphoma tumors demonstrates spatially restricted responses linked to drug mechanism. CIVO performance in canine lymphoma.

Fig. 1. A model to explain the pleiotropy of CEP290 disease.

Fig. 5. Octet BLI competition assay using D25 and motavizumab.

Fig. 6. Prolonged miR overexpression in the adult heart reduces fibrotic scar size but compromises cardiac function after MI. Prolonged miR

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Fig. 3. In vivo tumor responses are mechanism of action–specific and concentration-dependent. In vivo tumor responses are mechanism of action–specific.

Fig. 3 Measurement of real-world, high-risk opioid use events.

Fig. 3 Production of protein and Fe(II) at the end of growth correlated with increasing concentrations of ferrihydrite in the media that contained 0.2.

Fig. 1. The HCN channel blocker ivabradine (IVA) is analgesic in a mouse model of type 1 diabetes. The HCN channel blocker ivabradine (IVA) is analgesic.

Fig. 1 Crohn’s disease association within the LRRK2 locus.

Fig. 2. PlGF-2123–144 conjugation reduces systemic exposure to checkpoint blockade Abs and potential treatment-related toxicity. PlGF-2123–144 conjugation.

Fig. 2 Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes in cognition. Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes.

Fig. 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD. Purkinje cell quantification and hearing threshold in NPC.

Fig. 2. Overexpression of miR cluster in the developing heart results in increased cardiomyocyte proliferation and cardiomegaly. Overexpression.

Fig. 3 Mmp-2−/− mice are protected from obesity and leptin resistance.

Fig. 2 Neonatal ZIKV infection induces seizures in young mice and increases susceptibility to chemically induced seizures in adult mice. Neonatal ZIKV.

Fig. 2 In vitro and preclinical study with 18F-MPG.

Delineating cancer evolution with single-cell sequencing

Fig. 1. GDF15 is up-regulated with obesity, and AAV-GDF15 improves metabolic parameters in DIO mice. GDF15 is up-regulated with obesity, and AAV-GDF15.

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Fig. 5. High burdens of AA signature mutations and predicted immunogenicity in Taiwan HCCs. High burdens of AA signature mutations and predicted immunogenicity.

Effects of highly concentrated SFN provided as BSE in T2D patients

Fig. 3. miR overexpression leads to increased cell proliferation as well as altered differentiation and metabolism in cardiomyocytes. miR

Fig. 2 Heroin addiction contrasted with methadone maintenance.

Fig. 3. Association between peak CTL019 expansion and response.

Fig. 2 NGS bisulfite sequencing assay of DNA methylation in esophageal biopsies. NGS bisulfite sequencing assay of DNA methylation in esophageal biopsies.

Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.

Fig. 4 Gallium increases P. aeruginosa sensitivity to peroxides.

Fig. 3 Postnatal assembly of the humanized gut microbiota.

Fig. 2. Cellular response to FolamiRs in vitro.

Fig. 6. Connectivity and mobility maps for Lesotho.

Fig. 2 Time series of secularization versus GDP per capita, from four illustrative countries, over the 20th century. Time series of secularization versus.

Presentation transcript:

Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device for the seven study patients. (B) Plasma concentration of hPTH(1–34) versus time after injection of 20- and 40-μg doses of FORSTEO for the seven study patients. The 40-μg doses were administered as two sequential 20-μg injections. (C) Mean plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from the implanted microchip device (n = 7 patients × four doses) and injection of 2 × 20–μg doses of FORSTEO (n = 7 patients × two doses). Data are means ± SD. Robert Farra et al., Sci Transl Med 2012;4:122ra21 Copyright © 2012, American Association for the Advancement of Science